Paragon Biosciences-backed Castle Creek Biosciences Inc. pulled off an oversubscribed and upsized preferred stock financing of $112.8 million. The money should let the firm tie the bow on a phase III study and roll out top-line results of its lead ex vivo product candidate for recessive dystrophic epidermolysis bullosa (RDEB) called D-Fi (dabocemagene autoficel, also known as FCX-007).

Elasmogen Ltd. has secured a “transformational” £8 million (US$10 million) in new funding with which to move its shark-based, antibody-like constructs toward the clinic.